- Home
- STRR vs INDP Comparison
STRR vs INDP Comparison
Compare STRR & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRR
- INDP
- Stock Information
- Founded
- STRR 1985
- INDP 2000
- Country
- STRR United States
- INDP United States
- Employees
- STRR N/A
- INDP N/A
- Industry
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- STRR Health Care
- INDP Health Care
- Exchange
- STRR Nasdaq
- INDP Nasdaq
- Market Cap
- STRR 6.3M
- INDP 7.4M
- IPO Year
- STRR N/A
- INDP N/A
- Fundamental
- Price
- STRR $2.13
- INDP $0.34
- Analyst Decision
- STRR Strong Buy
- INDP Strong Buy
- Analyst Count
- STRR 1
- INDP 2
- Target Price
- STRR $5.00
- INDP $8.50
- AVG Volume (30 Days)
- STRR 61.6K
- INDP 760.1K
- Earning Date
- STRR 05-14-2025
- INDP 05-14-2025
- Dividend Yield
- STRR N/A
- INDP N/A
- EPS Growth
- STRR N/A
- INDP N/A
- EPS
- STRR N/A
- INDP N/A
- Revenue
- STRR $57,165,000.00
- INDP N/A
- Revenue This Year
- STRR $33.64
- INDP N/A
- Revenue Next Year
- STRR $22.87
- INDP N/A
- P/E Ratio
- STRR N/A
- INDP N/A
- Revenue Growth
- STRR 34.33
- INDP N/A
- 52 Week Low
- STRR $1.72
- INDP $0.31
- 52 Week High
- STRR $5.35
- INDP $2.76
- Technical
- Relative Strength Index (RSI)
- STRR 47.17
- INDP 39.35
- Support Level
- STRR $2.16
- INDP $0.33
- Resistance Level
- STRR $2.75
- INDP $0.37
- Average True Range (ATR)
- STRR 0.24
- INDP 0.04
- MACD
- STRR -0.00
- INDP 0.00
- Stochastic Oscillator
- STRR 32.80
- INDP 26.43
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.